AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States

Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016.(1,2)

from Breaking World Pharma News https://ift.tt/9ZCEawg